Janssen Collaborates with BARDA to Facilitate the Development of Corona Virus Vaccine

 Janssen Collaborates with BARDA to Facilitate the Development of Corona Virus Vaccine

Janssen, Imbruvica, (ibrutinib), Receives, EC, Marketing Authorisation, Approval, Chronic Lymphocytic Leukaemia

Shots:

  • Janssen partnered with BARDA to accelerate the development of its investigational coronavirus vaccine program. Both will partake to the research and development cost and mobilize resources to advance Janssen’s COVID-19 vaccine program
  • BARDA to provide a fund to expedite the development of vaccine into P-I study with an option for additional funding to advance a promising candidate while Janssen will upscale the production capacities to meet the public health needs
  • COVID-19 vaccine program will leverage Janssen’s AdVac and PER.C6 technologies, providing the ability to upscale production of the optimal vaccine therapy. The company utilizes its same technology in its Ebola vaccine, currently being administered in the Democratic Republic of Congo and Rwanda

Click here ­to­ read full press release/ article | Ref: J & J | Image: Janssen

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post